| Name | Polyinosinic-polycytidylic acid |
| Description | Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic double-stranded RNA (dsRNA) analog and an agonist of TLR3 as well as retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5). It can induce innate immune responses in mammals and serve as a vaccine adjuvant to enhance both innate and adaptive immunity, while modulating the tumor microenvironment and directly inducing apoptosis in cancer cells. Poly(I:C) is commonly used to establish acute respiratory distress syndrome (ARDS) animal models for studying immune responses and disease mechanisms. |
| In vitro | METHODS: Cervical cancer cells HeLa, SiHa, C33A and lung cancer cells A549 were treated with polyinosinic-polycytidylic acid (0.1-1 μg/mL) for 24 h, and cell death was detected using PI Staining.
RESULTS: Polyinosinic-polycytidylic acid effectively induced tumor cell death in a dose-dependent pattern. [1]
METHODS: Rat astrocytes were pretreated with polyinosinic-polycytidylic acid (10-20 μg/mL) for 12 h, and then exposed to oxygen-glucose deprivation (OGD) for 12 h. The morphology of the cells was examined by microscopy.
RESULTS: OGD induced significant cellular damage, and the cells appeared to be healthier in the group pretreated with polyinosinic-polycytidylic acid.Polyinosinic-polycytidylic acid exerted a certain degree of protective effect against OGD-induced damage in cultured astrocytes. [2] |
| In vivo | METHODS: To investigate the neuroprotective effects in an acute ischemia model, Polyinosinic-polycytidylic acid (0.3 mg/kg) was administered as a single intramuscular injection to Kun-Ming strain mice, and a model of arterial occlusion (MCAO) was constructed 2 h later.
RESULTS: Administration of polyinosinic-polycytidylic acid significantly attenuated neurological deficits in the ischemic striatum and cortex, reduced infarct volume, and suppressed the elevation of TNFα and IL-6 levels. [2]
METHODS: To test the antitumor activity in vivo, Polyinosinic-polycytidylic acid (1-100 μg/mouse) was intraperitoneally injected into a mouse model of metastatic tumors C57BL/6J induced by cutaneous melanoma B16-F10.
RESULTS: Lung tumor growth stopped after a single dose of Polyinosinic-polycytidylic acid. Polyinosinic-polycytidylic acid has potential antitumor activity in an established mouse model of lung metastasis. [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 128.80 mg/mL (191.84 mM), Sonication is recommended.
DMSO : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | Toll-like Receptor (TLR) | TLR3 | Polyinosinic-polycytidylic acid | Polyinosinicpolycytidylic acid | Polyinosinic polycytidylic acid | poly I:C | Inhibitor | inhibit |
| Inhibitors Related | Ethoxyquin | Kaolin | Stavudine | Aceglutamide | Urea | D(+)-Raffinose pentahydrate | Hydroxychloroquine | Metronidazole | Hydroxypropyl Cellulose | Formamide | Gluconate Calcium | Alginic acid |
United States
